Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

PharmTech spoke with Dr. Asma Patel, VP Global Commercial and Scientific Consulting–Drug Product, to find out how the growth ...

It is estimated that 70% to 80% 1 of small molecule drug candidates in development today can be classified as poorly water-soluble. Since poorly soluble drugs are difficult to formulate as tablets, ...

A global contract development and manufacturing organization focused on drug-device combination products. The company operates across multiple sites in the U.S. and the U.K., including a U.K.